8-K: Revolution Medicines Stockholders Affirm Board and Auditor at 2025 Annual Meeting

Revolution Medicines, Inc. announced the successful election of four Class II directors, ratification of PricewaterhouseCoopers LLP as independent auditors, and advisory approval of executive compensation at its 2025 annual meeting of stockholders.

Summary

• Revolution Medicines, Inc. held its 2025 annual meeting of stockholders on June 26, 2025.
• As of the record date of April 28, 2025, 186,261,742 shares of common stock were outstanding and entitled to vote.
• Stockholders elected four Class II directors to hold office until the 2028 annual meeting: Frank K. Clyburn, Jr., Sandra J. Horning, M.D., Sushil Patel, Ph.D., and Thilo Schroeder, Ph.D.
• Frank K. Clyburn, Jr. received 147,380,169 votes For, 512,898 Withheld, and 10,241,664 Broker Non-Votes.
• Sandra J. Horning, M.D. received 126,395,644 votes For, 21,497,423 Withheld, and 10,241,664 Broker Non-Votes.
• Sushil Patel, Ph.D. received 126,396,068 votes For, 21,496,999 Withheld, and 10,241,664 Broker Non-Votes.
• Thilo Schroeder, Ph.D. received 119,696,091 votes For, 28,196,976 Withheld, and 10,241,664 Broker Non-Votes.
• The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 157,875,830 votes For, 214,963 Against, and 43,938 Abstentions.
• Stockholders approved, on a non-binding, advisory basis, the compensation of the named executive officers with 145,265,825 votes For, 2,597,920 Against, 29,322 Abstentions, and 10,241,664 Broker Non-Votes.

Sentiment

Score: 7

Explanation: The successful passage of all proposals indicates stable corporate governance and shareholder alignment on key management and oversight functions, though some directors received notable 'withheld' votes.

Positives

• All three proposals presented at the annual meeting were approved by stockholders, indicating stable corporate governance.
• The ratification of PricewaterhouseCoopers LLP as the independent auditor passed with overwhelming support (157,875,830 votes For).
• The advisory vote on executive compensation also passed with strong support (145,265,825 votes For).

Negatives

• Three of the four elected Class II directors (Sandra J. Horning, M.D., Sushil Patel, Ph.D., and Thilo Schroeder, Ph.D.) received a notable number of 'Withheld' votes, ranging from 21,496,999 to 28,196,976, indicating some level of shareholder dissent or lack of full support for these nominees.

Industry Context

This filing details routine corporate governance matters for a publicly traded biotechnology company, reflecting standard practices for annual stockholder meetings in the industry. The successful passage of all proposals indicates a stable governance environment, which is typical for established companies in the biotech sector.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: The successful election of directors and ratification of auditors provide stability in corporate governance and financial oversight. The advisory vote on executive compensation offers shareholders a voice on management incentives and accountability.
• **Management**: The approval of executive compensation validates the current compensation structure, while the election of directors provides a clear board to report to and receive strategic guidance from.
• **Employees**: Stable governance and clear strategic direction from the board can contribute to a more secure and focused work environment, potentially impacting employee morale and retention.

Next Steps

• Elected Class II directors will hold office until the 2028 annual meeting of stockholders.
• PricewaterhouseCoopers LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Revolution Medicines, RVMD, SEC filing, 8-K, annual meeting, stockholder vote, corporate governance, director election, auditor ratification, executive compensation, biotechnology, pharmaceutical